The phase-3 ZEUS trial is currently testing whether targeting systemic inflammation with ziltivekimab, a monoclonal antibody that targets interleukin-6, can reduce the risk of recurrent cardiovascular events in patients with established ASCVD, CKD, and systemic inflammation (33). This evidence concerns the gene IL6 and atherosclerosis.